Abu Dhabi sovereign wealth fund Mubadala is investing in Swiss biotech firm Rejuveron Life Sciences AG. Rejuveron fouses on developing therapies to prevent or reverse diseases of aging and extend people's longevity. The European company raised around $75 million from a series B funding, which drew support from Mubadala's asset management unit Mubadala Capital. The new investment round was co-led led by Catalio Capital Management a life-sciences investment firm, and Apeiron Investment Group, the private investment company of German businessman Christian Angermayer. It reportedly values Rejuveron at close to $400 million. "[The company] has a closed $75 million financing round… with Mubadala joining the syndicate," Angermayer announced on social media on Tuesday.